x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Market Access Matters

Access Infinity

Brought to you by the team at Access Infinity, this podcast shines a spotlight on the people in market access. In each episode we interview a different industry professional to discover their journey into market access, what inspires them and what they feel is on the horizon for this this ever-changing and exciting industry.

science life sciences

All Episodes

26:37

Navigating Global Policy Shifts with Nikhil Taxak

Market Access Matters ·

2025/11/27

In this episode we sit down with Nikhil Taxak, Head of Pricing and Market Access Data Analytics at Access Infinity, to explore the rapidly evolving market access landscape. From the US Most Favored Nation (MFN) policy and Germany's Medical Research Act to surprising developments in Japan's pricing thresholds, Nikhil breaks down how these changes are reshaping pricing and reimbursement strategies worldwide. The conversation covers emerging regional patterns across Europe, North America, and ...

en-us

19:22

Beyond the Headlines: Understanding MFN's True Impact...

Market Access Matters ·

2025/10/02

In this episode, we're joined by Louisa Oliver Byrne, Senior Consultant at Access Infinity. We learn about the complexities of the Most Favored Nation (MFN) policy and its implications for pharmaceutical market access. Louisa shares insights from her recent research on MFN, exploring how direct-to-consumer pricing models might actually play out in practice, and why the policy's stated goals don't always align with likely outcomes. From "brown bagging" concerns to payer behaviour shifts, this ...

en-us

18:29

Revolutionary Strategies in Orphan Drug Development...

Market Access Matters ·

2025/08/28

In this episode, we invite Access Infinity Partner, Isabel Rubio back to the podcast to explore the unique challenges and innovative solutions reshaping market access and pricing within rare disease. Isabel shares insights from her extensive experience with due diligence assessments in orphan drug development, discussing three transformative strategies that are revolutionising how companies prove value in ultra-rare diseases. From multi-domain endpoints and visual evidence to pay...

en-us

30:22

Elevating launch excellence: The strategic value of...

Market Access Matters ·

2025/06/26

In this insightful episode we speak with Lizzie Shanahan, Global Access AI Strategy Lead at Sanofi. With over six years' experience at Sanofi and a rich background in commercial roles, Lizzie shares her unique journey into the world of market access and how her diverse experience shapes her approach to launch excellence. The conversation explores exciting developments in the industry, including the evolution of digital technologies and AI. Lizzie shares thoughtful insights on finding the righ...

en-us

18:35

Getting ready for the JCA: Why cross-functional...

Market Access Matters ·

2025/05/07

In this episode, we speak with Silvy Mardiguian, Senior Director and Head of HEOR for Europe & New Markets at BeiGene. Silvy has been co-leading BeiGene’s preparedness and organisational readiness for the new Joint Clinical Assessment (JCA) framework, which is going to significantly change the EU HTA landscape. Silvy shares key insights into some of the learnings and challenges she has encountered during this process and highlights why strong cross-functional collaboration has been...

en-us

13:37

The rise of multi-stakeholder capitalism in market...

Market Access Matters ·

2025/02/06

In this episode we chat with Jie Shen, who is Vice President Global Head Market Access at CSL. Having started her career in pharma before the market access function existed, Jie is an industry veteran. We cover the changes she's seen over the last 24 years, including multi-stakeholder capitalisation - what it means to Jie and why she feels it's important for market access leaders. The opinions shared in this podcast are Jie's own views.

en-us

42:03

Authentic leadership in Market Access with Katrin...

Market Access Matters ·

2025/01/21

We're kicking off 2025 with a fantastic podcast episode featuring Katrin Jack, Global Access Strategy Head at Galderma and President of the Healthcare Businesswomen's Association Zürich-Zug Chapter. This episode covers a lot of ground, from the 'sliding doors' moment that led Katrin into market access, to why she feels it's important for leaders to understand their core values (and stay true to them). Like many of our podcast guests, Katrin has an obvious passion for market access a...

en-us

15:05

Market Access in emerging markets with Ezgi Erdogan, GSK

Market Access Matters ·

2024/12/12

In this episode we speak with Ezgi Erdogan who is Oncology Market Access Director for Emerging Markets at GSK. In this discussion, we cover the unpredictability of emerging markets and the unique challenges this presents. Ezgi also shares her future predictions for access in emerging markets and talks about the importance of cross-functional collaboration in pharma to support the ever-changing landscape. The opinions shared in this podcast are Ezgi's own views.

en-us

27:41

Why Market Access requires unique thinking with UCB's...

Market Access Matters ·

2024/11/21

In this episode, we sit down with Pauline Payen, Director and Global Payer Strategy Lead for UCB’s Early Portfolio. Pauline shares her pragmatic insights into navigating the complexities of global market access. Throughout her career, Pauline hasn't been shy of new opportunities, which has led to her taking on roles in commercial and marketing to expand her experience. In this discussion, we explore why market access is her passion. A field where, as she says, "What you do, can be life-...

en-us

29:06

The role of resilience in market access with Rupert...

Market Access Matters ·

2024/10/17

In this episode we're joined by GSK's Head of Market Access for General Medicines, Rupert Gale. Rupert has been in pharma for over 27 years and is still going strong! In this discussion, he shares what resilience means to him and why he feels it's an important skill for market access leaders to leverage.Rupert shares some wonderful stories and advice that many of us can relate to and learn from. He also reveals what's keeping him passionate about access and value as he continues his care...

en-us

14:28

Exploring value demonstration in market access with...

Market Access Matters ·

2024/09/26

Korinna Karampampa, who is Director Market Access and Pricing at CSL Behring, joins this episode to share her views on sustainable economic development. Korinna shares what led her into market access and explains what drives her to think outside the box to build and demonstrate a product's current and future value. The opinions shared in this episode are Korinna’s own views and not representative of the organisation she is working for.

en-us

16:21

Connecting the dots: Market access in the biotech...

Market Access Matters ·

2024/09/05

In this episode we're joined by our first guest from Biotech - Ning Lu, who is Associate Director, International Pricing & Market Access at Blueprint Medicines.Ning shares her views on the complexities of market access and what makes the Biotech industry unique. She shares what inspired her to pursue a career in market access in biotechnology and why she feels it's a dynamic role and opportunity to 'connect the dots' with everything you learn. Ning references and recommends th...

en-us

18:05

What it takes to thrive as a strategic partner in...

Market Access Matters ·

2024/08/15

There’s no doubt that Market Access and Pricing leaders are fast becoming strategic partners in helping their wider organisations to understand the critical role of the function. In this episode, Marco Rauland from Merck KGaA joins us to explore this topic.Marco is Vice President Global Market Access and Pricing strategy, Pricing and Analytics. With over 25 years' experience in the field, he shares his views on the importance of clear communication when engaging all stakeholders and why MA&am...

en-us

19:25

Yvonne Hilsky, Moderna, on why it's important to...

Market Access Matters ·

2024/08/08

In this episode we're joined by Yvonne Hilsky who is Director of Market Access at Moderna. Having spent over 30 years in industry, Yvonne shares her views on what it takes to be successful in market access, including why making mistakes are an opportunity for growth. Yvonne explores why it's important to have strong foundations and understand the 'building blocks' of market access and shares great stories from the early stages of her career, which we're sure will resonate with man...

en-us

32:58

Raising awareness on Disability with Shubham Jadhav

Market Access Matters ·

2024/07/31

In this special episode which coincides with Disability Pride Month, we're joined by Senior Analyst Shubham Jadhav. Shubham has Becker Muscular Dystrophy (BMD) which is a form of muscular dystrophy and causes progressive muscle weakness. Shubham is very passionate about raising awareness of rare diseases, disability, inclusivity and accessibility. He joins Keshav Nagaraja to share his story and what we can all be doing to help those with disabilities. It's an inspiring discussion which ...

en-us

20:16

Exploring Canada's market access landscape with Sam...

Market Access Matters ·

2024/07/18

Sam is Head of Market Access Canada at Incyte Biosciences Canada and joins the podcast to discuss the evolving market access landscape in Canada. As part of his conversation with Louise, he describes the unique challenges that market access leaders in the country are facing. Useful resources referenced in this podcast: March 2024 - Canadian Health Policy Institute (Patented Medicines Expenditure in Canada 1990 – 2022)https://www.canadianhealthpolicy.com/product/patented-medicines-ex...

en-us

25:31

Market access challenges and changes: Joao Carrasco...

Market Access Matters ·

2024/07/11

In this episode we're joined by Joao Carrasco, Director, Global Market Access Team at Bayer Pharmaceuticals. With a 12+ year career spanning both HEOR and Market Access functions, Joao shares his journey and how his strong HEOR background informs his current role. Joao also explores the key pressures and challenges market access teams are facing and his views on the trends shaping the future of market access. The opinions shared in this episode are Joao's own views and not represent...

en-us

29:51

Sanofi's Becky Germino on communicating value, AI and...

Market Access Matters ·

2024/06/20

In this episode we look at market access through a different lens. We're joined by Becky Germino who has extensive experience in HEOR across a broad range of pharma organisations. Becky joined Sanofi this year as HEVA, Neurology and Immunology Team Leader and explains the key priorities for HEOR teams and their role in working closely with market access to help them define and communicate patient value.The discussion also explores the role of AI for HEOR and market access teams&nbs...

en-us

23:57

Sharing your market access story and demonstrating...

Market Access Matters ·

2024/03/21

en-us

24:39

Digitalisation of Market Access with Thomas Gilboy...

Market Access Matters ·

2024/03/07

en-us

31 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter